

Table S-1. Comparison between survivors and non-survivors (in-hospital) with non-HACEK Gram-negative IE.


	Survivors N= 50	Non-survivors N=8	p value
Demographic data			
Males	33 (66%)	6 (75%)	0.615
Age (median-range)	67.5 (54-76.25)	76.5 (73.5-81.75)	0.039
Type of endocarditis			
NVE	29 (58%)	5 (62.5%)	0.810
PVE	14 (28%)	2 (25%)	0.860
Device-related IE	7 (14%)	1 (12.5%)	0.909
Comorbidities			
Diabetes	17 (34%)	2 (25%)	0.615
Hemodialysis	0 (-)	1 (12.5%)	0.012
Malignancies	8 (16%)	2 (25%)	0.532
HIV infection	2 (4%)	0 (-)	0.565
Risk factors			
IVDU	5 (10%)	0 (-)	0.349
Central intravascular access	8 (16%)	4 (50%)	0.028
Implanted endovascular device*	13 (26%)	2 (25%)	0.952
Congenital heart disease	4 (8%)	0 (-)	0.407
Immunosuppression	8 (16%)	1 (12.5%)	0.800
Invasive procedures within 180 days			
Dental procedures	3 (6%)	0 (-)	0.477
Esophagogastrosocopy	1 (2%)	0 (-)	0.687
Colonoscopy	2 (4%)	2 (25%)	0.030
Cystoscopy	3 (6%)	0 (-)	0.477
Route of acquisition			
Community-acquired endocarditis	31 (62%)	1 (12.5%)	0.009
Healthcare-associated endocarditis	18 (36%)	6 (75%)	0.038
Nosocomial-acquired endocarditis	1 (2%)	1 (12.5%)	0.131
Complications			
Stroke	5 (10%)	2 (25%)	0.227
Embolism	11 (22%)	3 (37.5%)	0.341
Heart failure	8 (16%)	7 (87.5%)	<0.001
Septic shock	0 (-)	2 (25%)	<0.001
Arrhythmias	5 (10%)	0 (-)	0.349
Echocardiographic findings			
Cardiac abscess	3 (6%)	0 (-)	0.477
Perforation	3 (6%)	1 (12.5%)	0.501
Dehiscence	5 (10%)	1 (12.5%)	0.829
New regurgitation	7 (14%)	3 (37.5%)	0.102
Fistula	0 (-)	0 (-)	-
Presumed source of infection			
Genitourinary tract	16 (32%)	0 (-)	0.060
Skin	6 (12%)	2 (25%)	0.322
Non-oral gastrointestinal tract	7 (14%)	2 (25%)	0.425
Oral	3 (6%)	0 (-)	0.477
Other or unknown	21 (42%)	3 (37.5%)	0.810
MDR etiology	9 (18%)	7 (87.5%)	0.004
Treatment			
Surgery	23 (46%)	2 (25%)	0.265
Antibiotic therapy			

β -lact \pm aminoglycosides	21 (42%)	2 (25%)	0.361
carbapenem \pm aminoglycosides	3 (6%)	3 (37.5%)	0.007
β -lact + fluoroquinolones \pm aminoglycosides	9 (18%)	1 (12.5%)	0.702
carbapenem + fluoroquinolones \pm aminoglycosides	4 (8%)	1 (12.5%)	0.674
β -lact + carbapenem \pm other	9 (18%)	0 (-)	0.192
Others	4 (8%)	1 (12.5%)	0.674
β -lactam containing regimen	43 (86%)	3 (37.5%)	0.002

IE: infective endocarditis; NVE: native valve endocarditis; PVE: prosthetic valve endocarditis; IVDU: intravenous drug users; MDR: multidrug resistant.

Central intravascular access includes any of the following: arteriovenous fistula, chronic intravenous catheter, or acute central catheter.

Figure 1S. Etiology of non-HACEK Gram-negative IE



* Gram-negative coinfections include 1 *E. coli* + *Proteus mirabilis*; 1 *P. aeruginosa* + *P. fluorescens*; 1 *P. aeruginosa* + *Stenotrophomonas maltophilia*